Akoya Biosciences And NeraCare Sign Exclusive Global License Agreement To Develop And Commercialize Immunoprint Test For Early-Stage Melanoma Treatment Decisions, Leveraging Akoya's PhenoImager HT Platform To Address High-Risk Relapse Patients With...

Akoya Biosciences與NeraCare簽署獨家全球許可協議，以開發和商業化用於早期黑色素瘤治療決策的免疫打印測試，利用Akoya的PhenoImager Ht平台來解決高風險股票復發患者的...

Benzinga · 12/10 21:16

Akoya Biosciences And NeraCare Sign Exclusive Global License Agreement To Develop And Commercialize Immunoprint Test For Early-Stage Melanoma Treatment Decisions, Leveraging Akoya's PhenoImager HT Platform To Address High-Risk Relapse Patients With Potential Therapeutic Benefits

Akoya生物科學公司與NeraCare簽署獨家全球許可證協議，以開發和商業化免疫印記測試，用於早期黑色素瘤治療決策，利用Akoya的PhenoImager Ht平台，旨在爲高風險股票復發患者提供潛在的治療益處。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。